Interleukin-17 as a potential therapeutic target for chronic pain
Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side effects. Thus, new and effective treatments fo...
Main Authors: | Xiaojuan Jiang, Ruihao Zhou, Yujun Zhang, Tao Zhu, Qian Li, Weiyi Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.999407/full |
Similar Items
-
Kynurenine and Tetrahydrobiopterin Pathways Crosstalk in Pain Hypersensitivity
by: Ananda Staats Pires, et al.
Published: (2020-06-01) -
Editorial: Inflammatory pain: mechanisms, assessment, and intervention
by: Yong-Hui Zhang, et al.
Published: (2023-09-01) -
Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats
by: Tai-Kyung Seol, et al.
Published: (2017-10-01) -
Role of Specialized Pro-Resolving Mediators in Neuropathic Pain
by: Alessandro Leuti, et al.
Published: (2021-08-01) -
Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis
by: Yun Ge, et al.
Published: (2020-07-01)